Crucell NV  (CRXL) Trade Now »     Rate CRXL  -  Discuss CRXL  -  Add to Watch List        

As the largest pure-play vaccine company with a market cap of $1.2B (U.S. Dollar), Crucell (CRXL) represents a likely takeover target some time this year since the bid from Wyeth (WYE) fell through after the Pfizer (PFE) deal. Crucell offers a technology platform , development pipeline , marketed vaccines , a specialized sales force, and in-house manufacturing facilities.

 

One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies together.